General
Preferred name
fidrisertib
Synonyms
Blu-782 ()
IPN-60130 ()
ALK2-IN-1 ()
Ipn60130 ()
BLU-782 ()
P&D ID
PD164414
CAS
2141955-96-4
Tags
available
probe
drug candidate
Drug Status
investigational
Max Phase
2.0
Probe info
Probe type
experimental probe
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
4
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The chemical structure for fidrisertib was obtained from the WHO proposed INN list 126 (Jan 2022). This matches to the company code BLU-782 via PubChem. The compound is the subject of Blueprint Medicines' patent WO2021030386A1 , in which it is described as an activin receptor-like kinase (ALK) inhibitor, with preferred selectivity for ALK2 (ACVR1) and mutant forms of ALK2.
(GtoPdb)
MOA
Inhibitor
(Chemical Probes.org)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
7
Cayman Chemical Bioactives
ChEMBL Drugs
Chemical Probes.org
DrugBank
Guide to Pharmacology
MedChem Express Bioactive Compound Library
PKIDB
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
13
Molecular Weight
562.33
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
0
Rotatable Bonds
7
Ring Count
6
Aromatic Ring Count
3
cLogP
4.18
TPSA
84.67
Fraction CSP3
0.58
Chiral centers
1.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
TGF-beta/Smad
Target
TGF-β Receptor
ACVR1
Target class
Kinase
Target subclass
TKL
Source data
